Monte Rosa Therapeutics, Inc. growth

Reported trailing growth, forward expectations and three-year compound growth rates.

Trailing growth

Year over year

Revenue: -73.1%
EBITDA: —
EBIT: —
EPS: —
Free cash flow: —
Operating cash flow: —

Forward estimates

Revenue: -74.3%
EBITDA: +105.4%
EPS: +49.2%

Three-year CAGR

Revenue: +63.5%
EBITDA: +49.4%
EBIT: +33.2%
Net income: +46.9%
EPS: +53.1%
Free cash flow: —

Latest available reported and market-derived figures. A dash means the source dataset does not currently cover that metric; it does not imply a zero value.